{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:44:54Z","timestamp":1792507494669,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"Abstract<\/jats:title>\n Background<\/jats:title>\n Intravenous (IV) golimumab, a TNFi, is approved for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). We analyzed pooled safety results from three phase 3 IV golimumab trials in these rheumatologic diseases and hypothesized that the safety profile of IV golimumab would be similar to that established for other TNFi, including subcutaneous golimumab.<\/jats:p>\n <\/jats:sec>\n Methods<\/jats:title>\n Data from three double-blind, randomized trials of IV golimumab in patients with RA, PsA, and AS, each with a placebo-controlled period and an extension of active treatment, were included. Golimumab 2 mg\/kg was administered at weeks 0 and 4, then every 8 weeks through week 100 (RA) or week 52 (PsA, AS). Concomitant low-dose, oral corticosteroids were permitted. Concomitant methotrexate was required in the RA trial and permitted in the PsA and AS trials; placebo patients crossed over to golimumab at weeks 24 (RA, PsA) and 16\u00a0(AS), respectively. Adverse events (AEs), including infections, serious infections, malignancies, and major adverse cardiovascular events (MACE), were assessed through week 112 (RA) or week 60 (PsA, AS).<\/jats:p>\n <\/jats:sec>\n Results<\/jats:title>\n In total, 539 patients were randomized to placebo, and 740 patients were randomized to golimumab; 1248 patients received \u2265 1 golimumab administration. Among the placebo and golimumab patients, respectively, during the placebo-controlled periods, 40.6% and 50.3% had an AE, 2.4% and 3.8% had a serious AE, and 0.4% and 0.8% had a serious infection. Among all golimumab-treated patients, the numbers of events\/100 patient-years (95% CI) were as follows: AEs, 175.2 (169.0, 181.6); serious AEs, 12.7 (11.0, 14.5); serious infections, 3.4 (2.5, 4.4); active tuberculosis, 0.4 (0.1, 0.8); opportunistic infection, 0.2 (0.1, 0.6); malignancies, 0.4 (0.2, 0.9), and MACE, 0.5 (0.2, 1.0). There were no cases of lymphoma. Three (0.6%) placebo-treated patients and 6 (0.5%) golimumab-treated patients died during the studies. Concomitant methotrexate was associated with increased occurrence of elevated alanine transaminase levels and lower incidence of antibodies to golimumab. During the placebo-controlled periods, serious infections in the placebo and golimumab groups were more common in patients receiving concomitant low-dose oral corticosteroids vs. those not receiving corticosteroids.<\/jats:p>\n <\/jats:sec>\n Conclusions<\/jats:title>\n IV golimumab demonstrated a safety profile that was broadly consistent across these rheumatologic indications and with other TNFi, including subcutaneous golimumab. Concomitant methotrexate or corticosteroids were associated with an increase in specific AEs.<\/jats:p>\n <\/jats:sec>\n Trial registrations<\/jats:title>\n ClinicalTrials.gov<\/jats:ext-link>, NCT00973479<\/jats:ext-link>. Registered on September 9, 2009. ClinicalTrials.gov<\/jats:ext-link>, NCT02181673<\/jats:ext-link>. Registered on July 4, 2014. ClinicalTrials.gov<\/jats:ext-link>, NCT02186873<\/jats:ext-link>. Registered on July 10, 2014.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s13075-022-02753-6","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T07:05:49Z","timestamp":1647846349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3181-4205","authenticated-orcid":false,"given":"M. Elaine","family":"Husni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-891X","authenticated-orcid":false,"given":"Sergio","family":"Schwartzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn H.","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim H.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-5830","authenticated-orcid":false,"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"2753_CR1","volume-title":"Package insert","author":"ARIA Simponi","year":"2021","unstructured":"Simponi ARIA. Package insert. Horsham: Janssen Biotech, Inc; 2021."},{"issue":"3","key":"2753_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/annrheumdis-2012-201411","volume":"72","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Bingham CO 3rd., Mendelsohn AM, Kim L, Mack M, Lu J, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. 2013;72(3):381\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2753_CR3","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1136\/annrheumdis-2013-203742","volume":"73","author":"ME Weinblatt","year":"2014","unstructured":"Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, et al. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Ann Rheum Dis. 2014;73(12):2152\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2753_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/acr.22556","volume":"67","author":"CO Bingham 3rd","year":"2015","unstructured":"Bingham CO 3rd, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, et al. Maintenance of clinical and radiographic benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: week-112 efficacy and safety results of the open-label long-term extension of a phase III, double-blind, randomized, placebo-controlled trial. Arthritis Care Res (Hoboken). 2015;67(12):1627\u201336.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"11","key":"2753_CR5","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.40226","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheumatol. 2017;69(11):2151\u201361.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"2753_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/acr.23905","volume":"72","author":"ME Husni","year":"2020","unstructured":"Husni ME, Kavanaugh A, Murphy F, Rekalov D, Harrison DD, Kim L, et al. Efficacy and safety of intravenous golimumab through 1 year in patients with active psoriatic arthritis. Arthritis Care Res (Hoboken). 2020;72(6):806\u201313.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"2753_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3899\/jrheum.170487","volume":"45","author":"A Deodhar","year":"2018","unstructured":"Deodhar A, Reveille JD, Harrison DD, Kim L, Lo KH, Leu JH, et al. Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study. J Rheumatol. 2018;45(3):341\u20138.","journal-title":"J Rheumatol."},{"issue":"10","key":"2753_CR8","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3899\/jrheum.180718","volume":"46","author":"JD Reveille","year":"2019","unstructured":"Reveille JD, Deodhar A, Caldron PH, Dudek A, Harrison DD, Kim L, et al. Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: results through 1 year of the GO-ALIVE Study. J Rheumatol. 2019;46(10):1277\u201383.","journal-title":"J Rheumatol."},{"issue":"3","key":"2753_CR9","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/annrheumdis-2013-204195","volume":"74","author":"J Kay","year":"2015","unstructured":"Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015;74(3):538\u201346.","journal-title":"Ann Rheum Dis."},{"issue":"9990","key":"2753_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258\u201365.","journal-title":"Lancet."},{"issue":"12","key":"2753_CR11","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3899\/jrheum.160420","volume":"43","author":"J Kay","year":"2016","unstructured":"Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, et al. Five-year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2016;43(12):2120\u201330.","journal-title":"J Rheumatol."},{"issue":"4","key":"2753_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","volume":"17","author":"E Kemanetzoglou","year":"2017","unstructured":"Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-a blockers. Curr Neurol Neurosci Rep. 2017;17(4):36.","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"6","key":"2753_CR13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1093\u2013101.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"2753_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/14740338.2018.1448785","volume":"17","author":"S D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo S, Carriero A, Gilio M, Ursini F, Leccese P, Palazzi C. Safety of treatment options for spondyloarthritis: a narrative review. Expert Opin Drug Saf. 2018;17(5):475\u201386.","journal-title":"Expert Opin Drug Saf."},{"issue":"6","key":"2753_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3899\/jrheum.180681","volume":"46","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Noonan L, et al. Radiographic progression inhibition with intravenous golimumab in psoriatic arthritis: week 24 results of a phase III, randomized, double-blind, placebo-controlled trial. J Rheumatol. 2019;46(6):595\u2013602.","journal-title":"J Rheumatol."},{"issue":"3","key":"2753_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/rheumatology\/key309","volume":"58","author":"JH Leu","year":"2019","unstructured":"Leu JH, Adedokun OJ, Gargano C, Hsia EC, Xu Z, Shankar G. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Rheumatology (Oxford). 2019;58(3):441\u20136.","journal-title":"Rheumatology (Oxford)."},{"issue":"11","key":"2753_CR17","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","volume":"78","author":"S Safiri","year":"2019","unstructured":"Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463\u201371.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2753_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","volume":"47","author":"ME Husni","year":"2017","unstructured":"Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(3):351\u201360.","journal-title":"Semin Arthritis Rheum."},{"issue":"1","key":"2753_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","volume":"48","author":"L Scotti","year":"2018","unstructured":"Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(1):28\u201334.","journal-title":"Semin Arthritis Rheum."},{"issue":"5","key":"2753_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11926-019-0819-8","volume":"21","author":"M Garrido-Cumbrera","year":"2019","unstructured":"Garrido-Cumbrera M, Poddubnyy D, Gossec L, Galvez-Ruiz D, Bundy C, Mahapatra R, et al. The European map of axial spondyloarthritis: capturing the patient perspective-an analysis of 2846 patients across 13 countries. Curr Rheumatol Rep. 2019;21(5):19.","journal-title":"Curr Rheumatol Rep."},{"issue":"3","key":"2753_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10067-018-4397-3","volume":"38","author":"A Danve","year":"2019","unstructured":"Danve A, Deodhar A. Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities. Clin Rheumatol. 2019;38(3):625\u201334.","journal-title":"Clin Rheumatol."},{"issue":"4","key":"2753_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jcph.1348","volume":"59","author":"J Wronski","year":"2019","unstructured":"Wronski J, Fiedor P. The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: are TNF inhibitors safer than we thought? J Clin Pharmacol. 2019;59(4):445\u201362.","journal-title":"J Clin Pharmacol."},{"issue":"1","key":"2753_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12325-019-01145-8","volume":"37","author":"GR Burmester","year":"2020","unstructured":"Burmester GR, Gordon KB, Rosenbaum JT, Arikan D, Lau WL, Li P, et al. Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis. Adv Ther. 2020;37(1):364\u201380.","journal-title":"Adv Ther."},{"issue":"2","key":"2753_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/acr.22496","volume":"67","author":"DE Furst","year":"2015","unstructured":"Furst DE, Shaikh SA, Greenwald M, Bennett B, Davies O, Luijtens K, et al. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015;67(2):151\u201360.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"12","key":"2753_CR25","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1007\/s10067-018-4227-7","volume":"37","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clin Rheumatol. 2018;37(12):3285\u201396.","journal-title":"Clin Rheumatol."},{"issue":"4","key":"2753_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis. 2013;72(4):517\u201324.","journal-title":"Ann Rheum Dis."},{"key":"2753_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/annrheumdis-2021-221007","volume":"81","author":"IE Christensen","year":"2022","unstructured":"Christensen IE, Lillegraven S, Mielnik P, Bakland G, Loli L, Sexton J, et al. Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study. Ann Rheum Dis. 2022;81:398\u2013401.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2753_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124\u201331.","journal-title":"Rheumatology (Oxford)."},{"issue":"11","key":"2753_CR29","doi-asserted-by":"publisher","first-page":"870","DOI":"10.7326\/M20-1594","volume":"173","author":"MD George","year":"2020","unstructured":"George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study. Ann Intern Med. 2020;173(11):870\u20138.","journal-title":"Ann Intern Med."}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02753-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02753-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02753-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T07:08:37Z","timestamp":1647846517000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02753-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2753"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02753-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"25 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The GO-FURTHER, GO-VIBRANT, and GO-ALIVE trials were conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocols were approved by the Institutional Review Boards. All patients gave written informed consent before any study-related procedures were performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MEH has received\u00a0honoraria for participation in advisory boards (AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly,\u00a0Gilead, Janssen, Novartis, Pfizer, Regeneron, UCB).AD has participated in advisory boards (AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB), received research grants (AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, UCB), and participated in speakers\u2019 bureaus (AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, UCB).SS has received\u00a0consulting fees, research grants, speakers\u2019 bureau activity, or ownership or partnership (AbbVie, Amgen, Boston Scientific, Crescendo Bioscience, Dermtech, Eli Lilly, Genentech, Gilead Sciences, Janssen, Medtronic, Myriad Genetics, National Psoriasis Foundation, Novartis, Pfizer, Regeneron, Samsung, Sanofi, UCB) and participated in advisory boards (Jubilant, Myriad, Stelexis).AK has received research support and\/or consulting fees (AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly,\u00a0Genentech, Janssen, Merck, Novartis, Pfizer, UCB)SDC is an employee of Janssen Scientific Affairs, LLC, and owns stock in Johnson & Johnson.ECH, JHL, YZ, and KHL are or were employees of Janssen Research & Development, LLC, at the time this work was performed and own stock in Johnson & Johnson.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}